Skip to main content
Bloomberg

Novo Nordisk CSO on New Obesity Shot Results and Drug Pipeline

By
Watch on Grafa TV

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly's tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks on "Bloomberg Open Interest."

More from Australia

  1. Arika Resources begins 3,000-metre drilling at Pennyweight Point

  2. Core Energy Minerals starts 2,650m uranium drilling in Namibia

  3. COSOL signs $11M US transit contract

  4. ASIC plans to loosen pre-IPO advertising rules

  5. Auric Mining secures $17M capital placement

  6. Talga Group battery anode reaches 8,000 test cycles

View more

More ways to discover

Browse Australia newsDiscover ASX signalsBrowse all ASX stocksBrowse all ASX ETFsExplore Australia companiesFind the right ASX index